The Landscape of Targeted Therapies in TNBC

Elena Vagia(Northwestern University), Massimo Cristofanilli(Cornell University)

Cancers

April 8, 2020

10.3390/cancers12040916

Cited by 448

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

|The Lancet Oncology|2016|1.8k

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

|New England Journal of Medicine|2015|1.6k

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

|New England Journal of Medicine|2018|1.3k

Circulating giant macrophages as a potential biomarker of solid tumors

|Proceedings of the National Academy of Sciences|2014|278

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

|Critical Reviews in Oncology/Hematology|2018|268